سعر جيفتانا 60مجم /1.5 مل فيال 15 مل 2026

Jevtana (cabazitaxel) 60 mg/1.5 ml concentrate for intravenous infusion by Sanofi, a taxane antineoplastic used for metastatic castration-resistant prostate cancer.

• In combination with prednisone for metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimenPopulation: Adult menDailyMed (U.S. National Library of Medicine)

• Most common (10% or more) grade 1-4: anaemia, leukopenia, neutropenia, thrombocytopenia, diarrhoea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, haematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnoea, dysgeusia, cough, arthralgia and alopecia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Neutrophil counts of 1,500/mm3 or less; history of severe hypersensitivity to cabazitaxel or other drugs formulated with polysorbate 80; severe hepatic impairment (total bilirubin >3 x ULN).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - neutropenia: neutropenic deaths have been reported; monitor with frequent blood counts.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning - severe hypersensitivity (generalized rash/erythema, hypotension, bronchospasm) may occur; premedicate and stop the infusion immediately if severe reactions occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Nausea, vomiting and severe diarrhoea may occur (deaths related to diarrhoea/electrolyte imbalance reported); GI haemorrhage, perforation and neutropenic enterocolitis have been reported. Antiemetic prophylaxis is recommended.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir, voriconazole)May increase cabazitaxel plasma concentrations; avoid co-administration, or consider a 25% Jevtana dose reduction if a strong CYP3A inhibitor is required.DailyMed (U.S. National Library of Medicine)

• Safety and efficacy have not been established in females; no human data in pregnancy. In rats, intravenous cabazitaxel during organogenesis caused embryonic and fetal death at doses below the maximum recommended human dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.